Latest News

Lonza Signs Applied Protein Services Agreement with ImmuneMed for Immunogenicity Risk Assessment and Deimmunization of Novel Protein

Contract covers the immunogenicity screening of ImmuneMed’s novel investigational therapeutic compound Lonza will complete the pre-clinical screening followed by deimmunization

Lonza wins preclinical testing contract for ‘virus supressing factor’

Lonza will supply preclinical immunogenicity testing services for a candidate protein antiviral being worked on by South Korean biotech ImmuneMed.

More Info